GlassScriptPhysician profile
Irfan Iftikhar
NPI 1851357248
$7,325.31
in general payments reported to CMS, 2019-2025
43 companies · $908 in 2025
The $908 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $961 · 2021: $1,102 · 2022: $1,642 · 2023: $1,053 · 2024: $877 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,837.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,334.42 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $583.94 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $565.04 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $562.69 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $500.45 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $405.27 | 2019-2025 | Bodyguardian, Watchman Flx |
| Amarin Pharma, INC. | $384.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $383.79 | 2020-2025 | Farxiga |
| Abbott Laboratories | $375.59 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Sanofi-Aventis U.S. LLC | $215.78 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $192.86 | 2022-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $180.17 | 2019-2025 | Camzyos |
| Lundbeck LLC | $152.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.97 | 2021-2025 | Jardiance |
| Lexicon Pharmaceuticals, INC. | $114.68 | 2023-2024 | Inpefa |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.00 | 2019-2023 | Lifevest |
| Cleerly, INC. | $104.70 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Pfizer INC. | $96.08 | 2019-2025 | |
| Scpharmaceuticals INC. | $85.78 | 2023-2025 | |
| Astellas Pharma US INC | $85.09 | 2019-2020 | |
| Edwards Lifesciences Corporation | $78.83 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Actelion Pharmaceuticals US, INC. | $71.71 | 2024-2025 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $61.28 | 2025 | Amvuttra |
| Atricure, INC. | $51.30 | 2023 | |
| Lilly USA, LLC | $48.68 | 2022-2025 | Mounjaro, Zepbound |
| Agepha Pharma Fz LLC | $45.81 | 2024-2025 | Lodoco |
| Novo Nordisk INC | $43.17 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Cardiva Medical, INC. | $41.67 | 2022 | |
| Cvrx, INC. | $37.66 | 2021-2023 | Barostim Neo System |
| Bard Peripheral Vascular, INC. | $35.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $34.40 | 2020-2021 | |
| Angiodynamics, INC. | $26.30 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.72 | 2025 | |
| Allergan, INC. | $19.14 | 2019 | |
| Gilead Sciences, INC. | $19.13 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.70 | 2019 | |
| Genzyme Corporation | $17.51 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.13 | 2020 | |
| Althera Pharmaceuticals LLC | $15.39 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $15.38 | 2023 | Arcalyst |
| Preventice Services, LLC | $15.10 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.03 | 2024 | Edarbi |
| Medicure Pharma INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Iftikhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.